hrcak mascot   Srce   HID

ADMET and DMPK, Vol.6 No.1 Ožujak 2018.

Izvorni znanstveni članak
https://doi.org/10.5599/admet.6.1.470

In silico ADME in drug design – enhancing the impact

Susanne Winiwarter ; Drug Safety and Metabolism, IMED Biotech Unit, AstraZeneca, Gothenburg, Sweden
Ernst Ahlberg ; Drug Safety and Metabolism, IMED Biotech Unit, AstraZeneca, Gothenburg, Sweden
Edmund Watson ; Drug Safety and Metabolism, IMED Biotech Unit, AstraZeneca, Gothenburg, Sweden
Ioana Oprisiu ; Drug Safety and Metabolism, IMED Biotech Unit, AstraZeneca, Gothenburg, Sweden
Mickale Mogemark ; Drug Safety and Metabolism, IMED Biotech Unit, AstraZeneca, Gothenburg, Sweden
Tobias Noeske ; Drug Safety and Metabolism, IMED Biotech Unit, AstraZeneca, Gothenburg, Sweden
Nigel Greene ; Drug Safety and Metabolism, IMED Biotech Unit, AstraZeneca, Boston, US

Puni tekst: engleski, pdf (954 KB) str. 15-33 preuzimanja: 215* citiraj
APA 6th Edition
Winiwarter, S., Ahlberg, E., Watson, E., Oprisiu, I., Mogemark, M., Noeske, T. i Greene, N. (2018). In silico ADME in drug design – enhancing the impact. ADMET and DMPK, 6 (1), 15-33. https://doi.org/10.5599/admet.6.1.470
MLA 8th Edition
Winiwarter, Susanne, et al. "In silico ADME in drug design – enhancing the impact." ADMET and DMPK, vol. 6, br. 1, 2018, str. 15-33. https://doi.org/10.5599/admet.6.1.470. Citirano 13.12.2018.
Chicago 17th Edition
Winiwarter, Susanne, Ernst Ahlberg, Edmund Watson, Ioana Oprisiu, Mickale Mogemark, Tobias Noeske i Nigel Greene. "In silico ADME in drug design – enhancing the impact." ADMET and DMPK 6, br. 1 (2018): 15-33. https://doi.org/10.5599/admet.6.1.470
Harvard
Winiwarter, S., et al. (2018). 'In silico ADME in drug design – enhancing the impact', ADMET and DMPK, 6(1), str. 15-33. doi: https://doi.org/10.5599/admet.6.1.470
Vancouver
Winiwarter S, Ahlberg E, Watson E, Oprisiu I, Mogemark M, Noeske T i sur. In silico ADME in drug design – enhancing the impact. ADMET and DMPK [Internet]. 2018 [pristupljeno 13.12.2018.];6(1):15-33. doi: https://doi.org/10.5599/admet.6.1.470
IEEE
S. Winiwarter, et al., "In silico ADME in drug design – enhancing the impact", ADMET and DMPK, vol.6, br. 1, str. 15-33, 2018. [Online]. doi: https://doi.org/10.5599/admet.6.1.470

Sažetak
Each year the pharmaceutical industry makes thousands of compounds, many of which do not meet the desired efficacy or pharmacokinetic properties, describing the absorption, distribution, metabolism and excretion (ADME) behavior. Parameters such as lipophilicity, solubility and metabolic stability can be measured in high throughput in vitro assays. However, a compound needs to be synthesized in order to be tested. In silico models for these endpoints exist, although with varying quality. Such models can be used before synthesis and, together with a potency estimation, influence the decision to make a compound. In practice, it appears that often only one or two predicted properties are considered prior to synthesis, usually including a prediction of lipophilicity. While it is important to use all information when deciding which compound to make, it is somewhat challenging to combine multiple predictions unambiguously. This work investigates the possibility of combining in silico ADME predictions to define the minimum required potency for a specified human dose with sufficient confidence. Using a set of drug discovery compounds, in silico predictions were utilized to compare the relative ranking based on minimum potency calculation with the outcomes from the selection of lead compounds. The approach was also tested on a set of marketed drugs and the influence of the input parameters investigated.

Ključne riječi
Drug discovery; pharmacokinetics; in silico predictions; multi-parameter ranking

Hrčak ID: 196398

URI
https://hrcak.srce.hr/196398

Posjeta: 261 *